A Pre-Operative Window Study Evaluating Denosumab, a RANKligand (RANKL) Inhibitor and Its Biological Effects in Young Premenopausal Women Diagnosed With Early Breast Cancer

Trial Profile

A Pre-Operative Window Study Evaluating Denosumab, a RANKligand (RANKL) Inhibitor and Its Biological Effects in Young Premenopausal Women Diagnosed With Early Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Early breast cancer
  • Focus Pharmacodynamics
  • Acronyms D-Beyond
  • Most Recent Events

    • 01 Sep 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 01 Sep 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 01 Sep 2017 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top